Kronox Lab Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
KRONOX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts less than Nifty Microcap 250 and 5.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kronox Lab Sciences reported Q1 FY26 revenue from operations of ₹2,428.65 lakhs, down about 3.6% from ₹2,519.26 lakhs in Q1 FY25. Despite the topline dip, profit after tax inched up to ₹627.87 lakhs (vs ₹615.02 lakhs, up ~2.1%), helped by lower total expenses and higher other income of ₹87.32 lakhs. Profit before tax rose modestly to ₹844.05 lakhs from ₹830.79 lakhs, with EPS at ₹1.70 versus ₹1.67 a year ago. The auditor (Mahesh Udhwani & Associates) issued an unqualified limited review report with no qualifications or emphasis of matter. For full-year FY25, revenue stood at ₹10,019.39 lakhs and PAT at ₹2,546.72 lakhs, providing context for the quarterly run-rate.
Marginal YoY revenue decline is a mild negative, but stable margins and steady PAT growth signal operational resilience for shareholders; near-term stock reaction likely to be neutral as the numbers are broadly in line with prior periods.